Table. 3.

Adverse events (AEs) of lorcaserin

AuthorsNumber of subjectsDuration (months)*Common AEsSerious AEsSerious AEs assessed as possibly related to drug
Smith et al. (2010)3 (BLOOM)3,18224HeadacheCardiac disorder (2)
Upper respiratory infectionGastrointestinal disorder (4)
DizzinessGeneral disorder (2)
NauseaHepatobiliary disorder (6)
ConstipationImmune system disorder (1)
FatigueInfection (7)
Dry mouthInjury and poisoning (6) Metabolism
Abnormal laboratory test (1)
Metabolism disorder (1)
Musculoskeletal disorder (8)
Neoplasm (6)
Nervous system disorder (4)
Psychiatric disorder (1)
Reproductive system or breast disorder (8)
Respiratory disorder (3)
Fidler et al. (2011)20 (BLOSSOM)4,00812Headache(76)Syncope (1)
Upper respiratory infectionModerate depression (1)
NauseaAcute anxiety attack (1)
Dizziness
Fatigue
O'Neil et al. (2012)21 (BLOOM-DM)604 diabetic patients12Headache6.3% (10 mg BID)
Back pain8.4% (10 mg QD)
Nasopharyngitis
Nausea
Urinary tract infection
Cough
Symptomatic hypoglycemia
Fatigue
Gastroenteritis
Dizziness
Influenza
Procedural pain
Hypertension
Depression
Number in () means number of cases with the adverse events.

Occurred at a rate of ≥5% in any treatment group and more frequently than in placebo group (P,0.05).

Korean J Obes 2015;24:17~27 https://doi.org/10.7570/kjo.2015.24.1.17
© JOMES